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The impact of nurse-driven targeted HIV
screening in 8 emergency departments:
study protocol for the DICI-VIH cluster-
randomized two-period crossover trial
Judith Leblanc1,2*, Alexandra Rousseau3, Gilles Hejblum4, Isabelle Durand-Zaleski5,6,7, Pierre de Truchis8,
France Lert9, Dominique Costagliola4, Tabassome Simon10,11 and Anne-Claude Crémieux8,12
Abstract
Background: In 2010, to reduce late HIV diagnosis, the French national health agency endorsed non-targeted HIV
screening in health care settings. Despite these recommendations, non-targeted screening has not been
implemented and only physician-directed diagnostic testing is currently performed. A survey conducted in 2010 in
29 French Emergency Departments (EDs) showed that non-targeted nurse-driven screening was feasible though
only a few new HIV diagnoses were identified, predominantly among high-risk groups. A strategy targeting
high-risk groups combined with current practice could be shown to be feasible, more efficient and cost-effective
than current practice alone.
Methods/Design: DICI-VIH (acronym for nurse-driven targeted HIV screening) is a multicentre, cluster-
randomized, two-period crossover trial. The primary objective is to compare the effectiveness of 2 strategies
for diagnosing HIV among adult patients visiting EDs: nurse-driven targeted HIV screening combined with
current practice (physician-directed diagnostic testing) versus current practice alone. Main secondary objectives
are to compare access to specialist consultation and how early HIV diagnosis occurs in the course of the
disease between the 2 groups, and to evaluate the implementation, acceptability and cost-effectiveness of
nurse-driven targeted screening. The 2 strategies take place during 2 randomly assigned periods in 8 EDs of
metropolitan Paris, where 42 % of France’s new HIV patients are diagnosed every year. All patients aged 18
to 64, not presenting secondary to HIV exposure are included. During the intervention period, patients are
invited to fill a 7-item questionnaire (country of birth, sexual partners and injection drug use) in order to
select individuals who are offered a rapid test. If the rapid test is reactive, a follow-up visit with an infectious
disease specialist is scheduled within 72 h. Assuming an 80 % statistical power and a 5 % type 1 error, with
1.04 and 3.38 new diagnoses per 10,000 patients in the control and targeted groups respectively, a sample
size of 140,000 patients was estimated corresponding to 8,750 patients per ED and per period. Inclusions
started in June 2014. Results are expected by mid-2016.
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Discussion: The DICI-VIH study is the first large randomized controlled trial designed to assess nurse-driven
targeted HIV screening. This study can provide valuable information on HIV screening in health care settings.
Trial registration: ClinicalTrials.gov: NCT02127424 (29 April 2014).
Keywords: Decision support techniques, Emergency service, Hospital, HIV, HIV infections, Mass screening,
Nurses, Nursing, Prevention and control, Randomized controlled trial, Risk factors
Background
Optimizing HIV screening and reducing late diagnosis re-
main challenging issues in most countries [1–4]. Indeed,
late HIV diagnosis is associated with increased mortality
[5]. Moreover, the early introduction of antiretroviral
treatment provides net benefits on both morbidity and
mortality and reduces secondary transmission [6–8].
In France, although 5 million HIV screening tests are
performed each year [9], 25 % of new HIV diagnoses
were discovered at a late stage in 2013 (<200 CD4/mm3
or AIDS stage) [1]. Until 2010, screening strategies
aimed to encourage voluntary testing in specialist clinics
or through a primary care physician. In 2010, mirroring
what had already been suggested in other countries [10,
11], national recommendations encouraged French
healthcare staff to conduct non-targeted screening
among the 15 to 70 year old population, in order to
reach patients who wouldn’t voluntarily get tested [12,
13]. In this context, nurses were given the possibility of
offering, performing and delivering the result of an HIV
rapid test [14].
A study conducted in the metropolitan Paris area evalu-
ated the effectiveness of nurse-driven non-targeted HIV
screening in 29 public hospital Emergency Departments
(EDs) [15]. EDs were considered to be an ideal setting to
evaluate HIV screening strategies as they receive an aver-
age of 18.5 million visits annually, representing over 25 %
of the general population, including low-income groups,
the uninsured and other minorities at highest risk of HIV
exposure [16]. This study concluded that non-targeted
HIV screening was feasible and well accepted by patients
[15, 17]. However, only 18 patients out of 12,754 tested
patients were newly diagnosed, yielding a prevalence of
0.14 % (95 % CI [0.08 %–0.22 %]). These patients belonged
to the highest risk groups (i. e. men who have sex with
men (MSM), immigrants from generalized epidemic
areas). These results and those from other studies con-
ducted in France, in the United States and the United
Kingdom showed that non-targeted screening was feasible
in health care settings and that it provided a means to
reach a large number of patients [18–20]. Nevertheless,
the corresponding effectiveness in diagnosing HIV is sub-
ject to debate [15, 18, 21–23].
Studies evaluating nurse-driven HIV screening, com-
pared to screening performed by other health care staff,
showed a trend in higher test offering, better acceptance
and higher delivery rates with the implementation of
nurse-driven HIV screening [24]. However, a progressive
decrease in test offering rates from nurses and other
staff over time has been observed, most likely resulting
from of a loss of motivation related to the small number
of new diagnoses, which were concentrated in patients
at high risk of HIV exposure [20, 25, 26]. It has been
suggested that nurse-driven HIV screening in EDs was
possible on a wider scale over the long-term but would
be more feasible if it targeted a specific patient popula-
tion [27].
Recent studies conducted in the United States, the
United Kingdom and Spain have supported targeted
screening efforts [28–32]. Indeed, in these countries, the
hidden epidemic is less prevalent than expected [33] and
is, overall, concentrated in the highest risk groups
[15, 18, 34, 35]. The studies showed that targeted
screening was associated with identification of newly
HIV diagnoses when compared to non-targeted
screening [28, 31]. Only one study, conducted in a
single centre, did not observe any benefit from using
a targeted strategy [36]. However, in these studies,
less than 50 % of the population identified as being at
high risk of HIV exposure were actually tested [31, 36]
and cost-effectiveness analysis was not always provided,
thus requiring prospective multicentre trials with cost-
effectiveness analysis.
Rationale for the study design
The DICI-VIH study (a French acronym for Dépistage
infirmier ciblé du VIH, nurse-driven targeted HIV
screening) is a multicentre, cluster-randomized two-
period crossover trial comparing the effectiveness of tar-
geted screening combined with current practice to that
of current practice alone. Several study designs can be
explored to evaluate the effectiveness of targeted screen-
ing in health care settings. It could be compared either
to non-targeted screening or to current practice, which
is most often limited to diagnostic testing. However,
given both the low frequency of new diagnoses in non-
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targeted screening strategies and the burden of its imple-
mentation, non-targeted screening is not likely to be car-
ried out in France. Indeed, the results of a questionnaire
submitted in February 2013 showed that none of the
EDs included in the present study had adopted it. More-
over, studies show that non-targeted screening has not
been implemented in the United States or in the United
Kingdom several years after the publication of the rec-
ommendations [26, 31, 37, 38]. It therefore seems rele-
vant to evaluate the effectiveness of a combined strategy
of targeted screening and current practice in comparison
with current practice alone in order to draw conclusions
on whether or not it is worthwhile to recommend this
strategy in EDs.
Individual randomization in each ED would require
the intermittent involvement of nurses in targeted
screening, raising practical and organizational concerns,
as well as generalizability issues since a triage nurse
would never be able to intermittently apply the targeted
strategy. Therefore, a cluster-randomized design was
chosen to compare the 2 strategies. The centres were se-
lected based on the overall high risk of exposure to HIV
of their patient populations (see Study settings) and were
assumed to differ in terms of organization and care prac-
tices. Thus, a cluster-randomized two-period crossover
design, in which all clusters apply each strategy over 2
distinct periods (the objective of the randomization
process being to randomly assign which strategy is ap-
plied first in each cluster), enables the observation of
matched-pair differences between the strategies within
each ED [39, 40].
Primary objective
To compare the effectiveness of 2 strategies for diagnos-
ing HIV among adult patients visiting EDs: nurse-driven
targeted HIV screening combined with current practice
(physician-directed HIV diagnostic testing) versus
current practice alone.
Secondary objectives
The secondary objectives are to compare the 2 groups in
terms of:
– Access to a specialist consultation within 3 months
following the HIV diagnosis,
– Proportion of positive tests among tests performed,
– How early HIV diagnosis occurs in the course of the
disease.
During the period with nurse-driven targeted HIV
screening, the implementation of nurse-driven targeted
HIV screening is described by the proposition rate and
completion rate of the DICI-VIH questionnaire (Fig. 1),
the rate of patients found to be at risk, the test offering
rate, the acceptance rate, the screening rate, the rate of
positive tests and the evaluation of factors associated
with patient refusal to be tested. During this period, the
acceptability of nurse-driven targeted HIV screening by
providers and patient perceptions of the process are
assessed.
The costs and cost-effectiveness of the 2 strategies are
also compared.
Methods
Study design
The DICI-VIH study is a multicentre (n = 8), cluster-
randomized, two-period crossover trial.
The 2 strategies under comparison are:
– Current practice alone, consisting of physician-
directed HIV diagnostic testing, which involves a
medical interview and HIV test. This strategy is fur-
ther referred to as the control strategy (Fig. 2).
– Nurse-driven targeted HIV screening combined with
current practice. Nurse-driven targeted HIV screen-
ing by nurses consists in obtaining information on
patient risk status from the DICI-VIH self-reported
risk assessment questionnaire (Fig. 1) and, when ap-
plicable, offering, performing and delivering the re-
sult of a capillary HIV rapid test (Fig. 3). This
strategy is further referred to as the intervention
strategy.
EDs were identified before randomization. Eight EDs
were selected and consented to participate (see Study
settings). The randomization process assigned to each
ED which strategy is to be applied in the first period
(the alternative strategy being applied in the second
period), with half of the clusters applying the control
strategy in the first period, and the remaining half apply-
ing the intervention strategy (Fig. 2). The allocation
schedule was computer generated. Both study periods
are separated by a 4-week washout period. An equal
number of participants had to be included in each centre
for each period; thus the duration of the study periods
vary per ED and per period.
Study outcomes
Primary outcome
The main outcome measure is the proportion of new
HIV diagnoses among 18 to 64 year old patients present-
ing to the EDs (with the exception of those presenting
secondary to HIV exposure) during the inclusion
periods.
Secondary outcomes
The secondary outcomes are as follows:
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– Proportion of patients newly diagnosed HIV positive
who present for a specialist consultation within the
3 months following the test among those newly
diagnosed HIV positive,
– Proportion of new HIV diagnoses among tests
performed,
– How early diagnosis occurs in the course of the
disease, defined as the proportion of patients that
are newly diagnosed with CD4 counts >200/mm3
with no HIV-related symptoms, CD4 counts >350/
mm3 with no HIV-related symptoms, and CD4
counts >500/mm3 with no HIV-related symptoms.
During the intervention period, the implementation of
nurse-driven targeted HIV screening strategy is de-
scribed by:
– The distribution rate of the DICI-VIH questionnaire:
number of distributed questionnaires among in-
cluded patients unaware of their HIV status and
whose clinical presentation is compatible with the
completion of the questionnaire,
– The completion rate of the DICI-VIH questionnaire:
number of questionnaires completed among in-
cluded patients unaware of their HIV status and
whose clinical presentation is compatible with the
completion of the questionnaire,
– The rate of patients found to be at risk: number of
patients found to be at risk among included patients
who filled the questionnaire,
– The test offering rate: number of patients who were
offered a rapid test by nurses among patients found
to be at risk,
Fig. 1 DICI-VIH questionnaire
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– The acceptance rate: number of patients who
accepted to be tested among patients who were
offered a rapid test,
– The screening rate: number of rapid tests performed
by nurses among patients found to be at risk,
– The rate of positive tests and rate of confirmed
positive tests among rapid tests performed by
nurses,
– The factors associated with patient refusal to be
tested.
During this period, the acceptability of nurse-driven
targeted HIV screening by providers and patient percep-
tions of the process are described qualitatively, as de-
tailed in section 9.
The costs and cost-effectiveness of each strategy are
also evaluated and are detailed in section 9.
Study settings
The evaluation of nurse-driven targeted HIV screen-
ing is conducted in the metropolitan Paris area (Ile-
de-France), which is one of the most affected regions
of France, with 42 % of France’s new HIV diagnoses
annually [1, 9]. The selection of public hospital EDs
was undertaken based on the overall high risk of ex-
posure to HIV of their respective patient popula-
tions. Using the data from a previous study
undertaken in 29 EDs reflecting the diversity of the
ED settings in the Paris metropolitan area [15], 8
centres were selected as 8 % of their patients met
the main targeted screening criteria (MSM, Sub Sa-
haran African origin). The heads of the 8 EDs and
their nurse supervisors were contacted and asked to
participate by the research team. They all agreed to
participate.
Fig. 2 DICI-VIH flow diagram following CONSORT
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Study participants
All patients aged 18 to 64 consulting in the ED during
the recruitment periods are included, with the exception
of those presenting secondary to HIV exposure through
sexual or blood contact of less than 48 h.
During the nurse-driven targeted HIV screening
period, the DICI-VIH questionnaire is distributed to pa-
tients unaware of their HIV status and whose clinical
presentation is compatible with providing consent and
with the completion of the questionnaire (the question-
naire is not distributed to patients with acute life-
threatening conditions, altered consciousness, severe
neuropsychiatric disorders, language barriers or who are
under arrest).
Study strategies
Control strategy
During the control period, the physician can offer to
perform an HIV test (rapid test or standard enzyme
linked immunosorbent assay and Western blot confirm-
ation) based on the presence of HIV-related symptoms,
following current practice (Fig. 3).
Intervention strategy
During the intervention period, the HIV rapid test is of-
fered to patients identified as being at risk of HIV expos-
ure based on their answers to the DICI-VIH
questionnaire (at least 1 YES to the 5 following ques-
tions: lifetime exposure to male-to-male sexual contact,
>5 sexual partners in the last 12 months, Sub-Saharan
African origin or partner from a Sub-Saharan country in
the last 10 years, lifetime injection drug use), Fig. 1. The
triage nurse offers screening prior to the medical exam-
ination (Fig. 3).
Once the patient provides consent, the rapid test
(VIKIA HIV1/2, bioMérieux, Marcy l’Etoile, France) is
performed. If the result is reactive or if 2 sequential
rapid test results are invalid, the nurse performs a blood
draw for standard enzyme linked immunosorbent assay
and Western blot confirmation. A follow-up visit with
an infectious disease specialist (who has agreed to serve
as a referral in the study) is arranged within 72 h. The
infectious disease specialist can contact the patient by
phone if he/she does not attend the initial appointment.
If the rapid test is negative, the nurse recommends re-
peating the test when exposure is recent.
Fig. 3 DICI-VIH flow chart
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If the triage nurse does not offer the test to a patient
because he/she does not meet risk criteria or declines
the test or if the triage nurse omits to offer it, the phys-
ician can offer an HIV test to patients presenting with
HIV-related symptoms, following current practice.
Study procedures
Prior to the start of the intervention period with nurse-
driven targeted screening, staff members (nurses, nurse
supervisors, physicians, nurse assistants) of the corre-
sponding ED will have participated in a 60-min training
session organized by the research coordinator and an in-
fectious disease specialist. The training session includes
an educational lecture, an HIV rapid test demonstration,
hands-on practice, and information about how to dis-
close test results, whether negative or reactive.
In each participating ED, the nurses are supported
by a clinical research nurse or clinical research assist-
ant and are responsible for daily patient inclusion and
for collecting study data in the electronic case-report
form (eCRF).
The research coordinator meets the ED teams bi-
monthly to discuss any issues related to the protocol
and to evaluate study progress. In addition, a one-page
study newsletter is regularly given to the ED teams.
Designing the DICI-VIH self-reported risk assessment
questionnaire
The DICI-VIH self-reported risk assessment question-
naire (Fig. 1), adapted to the French population, was de-
signed in 2012 by an expert panel to help identify
patients who have an increased probability of undiag-
nosed HIV infection. The questionnaire is based on vari-
ables associated with HIV infection (male-to-male sexual
contact, multiple partners, country of birth and partner’s
country of birth, lifetime injection drug use) [35, 41, 42].
Question wording was similar to that used for the Den-
ver score [31, 43] and in pre blood donation assessments
(France, United States, United Kingdom) so as to ensure
the questionnaire’s acceptability.
To our knowledge, no score has been developed in
France to predict the likelihood of unknown positive
HIV status in the general population. Previous studies
on non-targeted screening in metropolitan Paris failed to
provide sufficient information to enable the building of
such a score due to the small number of identified posi-
tive HIV cases [15, 20]. Furthermore, the scores and pre-
dictive factors published in the international literature
cannot be used as they were most often developed in the
United States and are not applicable to the French con-
text [32, 43–51].
The DICI-VIH questionnaire was tested in February
2013 in one study centre. Participants completed the 7-
item DICI-VIH questionnaire and a 6-item survey
assessing its acceptability on a 4 point-scale rating their
understanding of- and comfort with the questions. This
questionnaire was submitted to patients presenting to
the ED during 3 half days in the same week. It was com-
pleted by 52 of the 54 patients (24 male, 30 female) who
were invited to participate, with a response rate of 96 %.
Only 2 patients refused to participate due to their clin-
ical presentation, which was not compatible with the
completion of the questionnaire. No difficulties in an-
swering the questionnaire or issues of confidentiality
were identified. Ninety-eight per cent of the participants
(51/52) were comfortable with the questions and were
willing to disclose their HIV risks knowing that the
healthcare staff would see the information. Only 1 pa-
tient declared that he was not comfortable answering
the question relating to male-to-male sexual contact.
18 % of patients disclosed at least 1 risk (n = 2 for male-
to-male sexual contact, n = 4 for > 5 sexual partners, n =
1 for Sub Saharan African origin, n = 1 for partner from
a Sub Saharan country, n = 1 for injection drug use).
Data collection and management
During both periods, general data of patient flow are
collected on a daily basis in each centre by the research
team on a paper CRF, including:
 Total number of patients,
 Number of patients aged 18 to 64 not presenting
secondary to HIV exposure,
 Number of patients aged 18 to 64 not presenting
secondary to HIV exposure who are tested for HIV
(either rapid test or Standard enzyme linked
immunosorbent assay) as ordered by a physician,
 Number of patients whose HIV diagnosis is
confirmed to be positive by serology,
 Number of patients newly diagnosed HIV positive
presenting for a specialist consultation and their
characteristics (CD4 counts, viral load, HIV, HBV,
HCV and Syphilis serological status and their
clinical presentation). These data are downloaded
with the help of the laboratory personnel in each
hospital and the infectious disease specialist.
Additionally, during the nurse-driven targeted HIV
period, data are also recorded by the research team on a
paper CRF:
 Number of patients aged 18 to 64 not presenting
secondary to HIV exposure, unaware of their HIV
status and whose clinical presentation is compatible
with the completion of the questionnaire,
 Number of patients who were distributed the DICI-
VIH questionnaire and who filled it out,
 Number of patients found to be at risk,
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 Number of patients found to be at risk and who
were offered a rapid test by a nurse,
 Number of patients found to be at risk and tested by
a nurse,
 Number of patients tested with a reactive rapid test
(confirmed or not confirmed positive by serology),
 Number of patients whose HIV diagnosis is
confirmed to be positive by serology.
With the help of the research team, nurses collect in-
dividual data from the DICI-VIH questionnaire (patient
risk assessment on the patient page (Fig. 1) and offering
rate, acceptance rate and screening rate on the nurse
page) on an e-CRF. The quality of these data is con-
trolled on site by the monitoring team.
Upon study completion, ED flow data, including pa-
tient baseline characteristics, degree of severity and time
spent in the ED will be extracted from the electronic
patient-level ED database.
A data manager collects all study data on a secure
password-protected server. A quality team, independent
from the coordination team, will perform an internal
audit of data completeness and will ensure the individual
data matches the data collected on the e-CRF.
Sample size
We assumed that the crossover design, which results in
matched-pair data within each centre (increased statis-
tical power of the comparison test), and the effect of the
cluster study design (increased between-cluster variabil-
ity decreasing the statistical power) cancel each other
out, see [52] webappendix p1, [53].
The sample size calculation was performed with a
comparison between 2 proportions with the hypothesis
of superiority.
We hypothesize that, during the intervention period,
the proportion of newly diagnosed HIV patients is simi-
lar to that found in non-targeted screening combined
with current practice. Based on previous data [15], the
proportion of new HIV diagnoses was expected at 1.04
and 3.38 per 10,000 patients, in the control strategy and
in the intervention strategy respectively. Accordingly, a
study sample of 140,000 patients which corresponds to
the screening of 8,750 patients per centre and per
period, would lead to a statistical power of 80 % with a
5 % two-sided type 1 error rate, using Fisher’s exact test
(Pass v11.0.1 software [54]).
Statistical analysis
The statistical analysis will follow the intention-to-treat
approach. A statistical analysis report will be written to
describe all the findings according to the CONSORT
statement recommendations [55].
The baseline characteristics of centres and patients
will be described for each intervention group. Categor-
ical variables will be described as numbers and percent-
ages. Continuous variables will be reported using means
and standard deviations or medians and interquartile
ranges.
For the primary outcome, we will use generalized
linear mixed modelling (Poisson mixed model) to
provide statistical estimates controlling for each clus-
ter, with the strategy intervention as a fixed effect
and clusters as a random effect. The impact of the
implementation order of intervention and control
organization in the 2 periods on this outcome will be
assessed. Additional sensitivity analysis could be per-
formed with a permutation test.
Given the low rate of false positive rapid tests, any
missing value (reactive rapid test not confirmed) will be
considered as a success (positive test) in the analysis.
Additional sensitivity analyses will also consider missing
values as 1) success in the intervention group (HIV+
diagnosis confirmed) and failure in the control group
(HIV- diagnosis confirmed); 2) failure in the intervention
group and success in the control group.
The secondary outcomes regarding the presentation
of patients newly diagnosed HIV positive for specialist
consultation within 3 months and the rate of positive
tests will be compared in the 2 groups using Pearson’s
χ2 test or Fisher’s exact test when applicable. Any
missing value for the rate of positive tests (reactive
rapid test not confirmed) will be considered as a
success (positive test).
Early diagnosis measured as the proportion of patients
with CD4 counts >200/mm3 with no HIV-related symp-
toms will be compared between the 2 groups using Pear-
son’s χ2 test or Fisher’s exact test when applicable. The 2
other thresholds (>350/mm3, >500/mm3) with no HIV-
related symptoms will also be explored. The missing
values will not be replaced.
Results of the DICI-VIH questionnaires will be
described.
Additional analyses
Factors associated with patient refusal of nurse-driven tar-
geted HIV screening
In half the centres, all patients who have completed the
DICI-VIH questionnaire, are at risk of HIV exposure
and eligible for nurse-driven targeted HIV screening are
considered over randomly selected 32-h observation pe-
riods of ED activity during 7 consecutive days. The pa-
tient characteristics reported in the DICI-VIH
questionnaire, history of HIV testing and perceived HIV
risk will be compared between patients refusing to be
tested and patients accepting the rapid test in the
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context of nurse-driven targeted HIV screening. A de-
scriptive analysis of these data will be performed.
Patient perceptions of nurse-driven targeted HIV screening
The respondents’ perceptions of the DICI-VIH question-
naire, of being offered an HIV rapid test, of result dis-
closure and of HIV screening in general are collected
over a week-long period in 4 of the centres. The study
team interviews all the patients who fill out the DICI-
VIH questionnaire using a face-to-face questionnaire. A
descriptive analysis of these data will be performed. The
patients refusing to fill the DICI-VIH questionnaire are
not considered in this study; this is a limitation of the
evaluation.
Acceptability of nurse-driven targeted HIV screening by
providers
The acceptability of nurse-driven targeted HIV screening
by providers will be studied using an ethnographic ap-
proach (direct observation, in depth interviews and
questionnaires). The objectives of this qualitative section
are to 1) identify individual, team-related and structural
factors that might influence the implementation of the
intervention, 2) evaluate how the staff perceived the im-
plementation of the strategy (during the trial and in rou-
tine practice) and 3) evaluate the nurse’s role and
involvement in the process.
In each centre, nurses answer a short questionnaire
before and after the study completion in order to evalu-
ate their perceptions of the intervention strategy and if/
how their perceptions evolve after the study. The
questions refer to nurse competences related to the
intervention strategy and to the potential long-term im-
plementation in EDs. In each centre, at the end of the
study, individual in depth interviews with nurses, nurse
assistants, nurse supervisors, physicians and directors of
nursing practice are conducted in order to qualitatively
collect their perceptions after the implementation of the
evaluated strategy.
With the help of the questionnaires, in depth inter-
views and direct observation during the trial conducted
by the research coordinator, factors influencing the par-
ticipation in the nurse-driven targeted HIV screening are
collected. These factors will be analysed in association
with the centre's overall nurse test offering rate.
Cost and cost-effectiveness evaluation
The economic evaluation will have 3 phases: 1) estima-
tion of the intervention strategy costs per patient tested
through micro costing, 2) comparison of diagnostic costs
with and without targeted screening, 3) estimation of an
incremental cost-effectiveness ratio if the strategy with
the greatest effectiveness also has the highest cost. In
this case, the effectiveness of this strategy, compared to
the alternative strategy, will be expressed in terms of
extra HIV patient newly diagnosed. If the intervention
strategy shows both effectiveness and cost-effectiveness,
we will consider modelling the impact on the epidemic's
dynamics in Paris metropolitan area.
Organization of the trial
The study adheres to the Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) state-
ment [56].
Ethical aspects
The study was approved by the Ile-de-France XI Com-
mittee for Patient Protection (No. 13084, January 21,
2014, N°IDRCB: 2013-AO1569-36) and by the French
Data Protection Authorities responsible for database
security (Comité Consultatif sur le Traitement de l’In-
formation en matière de Recherche dans le domaine
de la Santé (CCTIRS) and Commission Nationale de
l’Informatique et des Libertés (CNIL)).
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Data monitoring
A data monitoring committee is established and brings
together the contributors of the protocol, 2 external
public health specialists and an ED nurse supervisor.
This committee is involved in the organization of the
trial and reviews the quality of the data collected. During
the trial, the members can decide which measures to
adopt in case of unforeseen circumstances.
Discussion
In countries with concentrated epidemics, targeted HIV
screening strategies have not been sufficiently evaluated
[31]. The DICI-VIH trial was designed to assess the ef-
fectiveness and cost-effectiveness of nurse-driven tar-
geted HIV screening compared to routine practice in
French EDs. To date, no multicentre randomized con-
trolled trial has evaluated the effectiveness of targeted
HIV screening compared to current practice in health
care settings.
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Several features of the trial are of particular interest.
First, the trial will evaluate the feasibility of a targeting
tool used by nurses on a large panel of patients in the
context of EDs. Following the example of a previous
study, which used a self-administered questionnaire [15],
the present study is based on the DICI-VIH self-
reported risk assessment questionnaire, thus avoiding
having to verbally ask patients personal and sensitive
questions. Moreover, in order to minimize the impact of
the screening strategy on the clinical care process, the
questionnaire is distributed during patient admission
and the triage nurses receive patients who have already
filled out the DICI-VIH questionnaire.
Secondly, this study enables the evaluation of the inter-
vention’s effectiveness as well as the staff ’s perceptions on
the acceptability of the intervention by using a mixed
method approach (quantitative and qualitative data). In-
deed, both patient and staff perceptions of the interven-
tion are necessary prerequisites for the successful
implementation of a new HIV screening program [57].
Thirdly, in the context of limited financial resources, it
is essential to evaluate public health interventions before
their implementation. The costs and cost-effectiveness
of nurse-driven targeted HIV screening will therefore be
evaluated.
Fourth, the chosen cluster-randomized and crossover
design has a methodological advantage. It reduces the
risk of contamination between both strategies. With in-
dividual randomization, nurses would intermittently
apply the targeted strategy and the risk of contamination
may decrease observed outcome differences between the
2 strategies. Moreover, this discontinuous organization
could never be applied in routine practice in EDs, raising
major concerns in terms of generalizability of the results
of such a study.
There are some limitations to consider with the
present study design. First, due to the consecutive inclu-
sion periods in this cross-over study, there could be a
risk of inter-period contamination in the centres that re-
ceived the intervention first. The risk will be assessed
during the analysis. However, this risk should be low as
the periods are separated by a 4-week washout period
and because providers are different in the 2 groups. In-
deed, screening is offered by nurses during the interven-
tion period whereas only physicians are involved during
the control period. Second, in a trial requiring active pa-
tient and provider participation, the implementation of
the 2 strategies will be associated with some variability
between clusters regarding the proportion of new HIV
diagnosis. This is not a default on the contrary; the
cluster-randomized two-period crossover design is actu-
ally an asset for the estimation of between-cluster vari-
ability [58]. Moreover, assessing and understanding
differences in intervention effectiveness and adherence
from one ED to another is a core part of the analysis. In
addition, the factors associated with screening refusal
will be evaluated in the present study. They have already
been explored in studies on non-targeted screening and
results suggest that refusal is not associated with belong-
ing to the highest risk groups [15, 59–61]. Third, the
number of clusters (n = 8) is relatively small, with an as-
sociated limited statistical power of the test of inter-
action between intervention order and intervention
effectiveness [62].
If the effectiveness of the intervention strategy is con-
firmed, the results of this trial could contribute to the
development of recommendations and nurse-driven tar-
geted HIV screening could be generalized in the French
EDs of areas with high HIV prevalence. Finally, although
the results may not be directly applicable to other coun-
tries, they could be helpful for decision makers in coun-
tries with concentrated epidemics.
Conclusion
To our knowledge, the DICI-VIH study is the first large
randomized controlled trial designed to assess the bene-
fits of nurse-driven targeted HIV screening in EDs. Find-
ings from this study will contribute to the development
of HIV screening strategies, and to the promotion of
nurse participation in prevention and public health
programs.
Trial status
Inclusions started in June 2014. Initial results are ex-
pected by mid-2016.
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